Guidance on new provisions for traditional herbal medicinal products and homeopathic medicinal products

AI Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued guidance regarding the registration of traditional herbal and homeopathic medicines following the Windsor Framework agreement. While the broader Windsor Framework implementation begins on January 1, 2025, registrations for traditional herbal medicines (THR) and homeopathic products under the simplified registration scheme remain outside its scope, continuing under the regulatory provisions established in January 2021. For traditional herbal medicines, the Human Medicines Regulations 2012 (as amended) dictate specific evidence requirements. Great Britain-only registrations (THR GB) allow for 15 years of traditional use evidence from a wider range of countries with equivalent pharmacovigilance standards. Conversely, UK-wide or Northern Ireland-only registrations require evidence from EU/EEA countries exclusively. Homeopathic medicines follow similar regional splits. The simplified registration scheme for Great Britain accepts pharmacopoeias from the UK, Europe, or MHRA-approved lists. However, Northern Ireland and UK-wide registrations must adhere to the EU definition, utilizing European or EEA state pharmacopoeias. Notably, products under the Homoeopathic National Rules scheme fall within the Windsor Framework's scope. From January 1, 2025, these will be authorized on a UK-wide basis only. Applicants must ensure their evidence of traditional use and manufacturing procedures align with the specific regional requirements for Great Britain, Northern Ireland, or UK-wide marketing. While this is policy guidance rather than an inspection report, failure to comply with these evidence and pharmacopoeia standards will prevent successful product registration.